NeuroSense’s PrimeC Shows Compelling Results for ALS Survival in Novel iPSC Model

Key Points:

Groundbreaking study utilized iPSCs derived from blood samples of ALS patients to evaluate the survival rate of induced motor neurons when treated with NeuroSense’s product candidate, PrimeC.

In collaboration with the University of Southern California’s Ichida Stem Cell Lab, PrimeC significantly increased the survival rate of induced motor neurons in an in vitro study iPSCs generated from people living with ALS.

In a groundbreaking collaborative effort, NeuroSense Therapeutics Ltd. announced the results of a recent study that could be life-changing for those suffering from amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease. The study, conducted by Dr. Justin Ichida at the University of Southern California’s Stem Cell Ichida Lab, has shown that NeuroSense’s PrimeC significantly increased the survival rate of induced motor neurons in an innovative in vitro model using induced pluripotent stem cells (iPSCs) derived from ALS patients. This discovery has the potential to revolutionize ALS treatment and bring hope to those affected by this debilitating disease.

Amyotrophic lateral sclerosis, commonly known as ALS or Lou Gehrig’s disease, is a progressive and fatal neurodegenerative disease that affects the motor neurons in the brain and spinal cord. As the neurons degenerate, patients experience muscle weakness, loss of motor function, and, ultimately, paralysis. There is currently no cure for ALS, and available treatments provide only limited relief.

The PrimeC Study, Transforming ALS Research

NeuroSense’s PrimeC, a candidate compound developed for ALS treatment, has shown remarkable promise in the fight against this devastating disease. Dr. Ichida’s study utilized iPSCs derived from blood samples of ALS patients to evaluate the survival rate of induced motor neurons when treated with PrimeC compared to its individual components, ciprofloxacin and celecoxib. The results were highly compelling.

PrimeC demonstrated a significant beneficial effect relative to each of its components alone. It proved to be a powerful combination, aligning the neuronal survival rate with that of healthy controls. The iPSCs treated with PrimeC displayed increased neuronal survival compared to ALS control cells, effectively restoring their survival rate to a level similar to that of healthy individuals.

This study builds on earlier research conducted independently by Dr. Ichida, which demonstrated that NeuroSense’s combination therapy, PrimeC, performed exceptionally well in improving motor neuron survival. In fact, PrimeC stood out among several other ALS drugs in development and even rivaled two FDA-approved ALS drugs: Amylyx Pharmaceuticals’ combination therapy, RELYVRIO, and Mitsubishi Tanabe’s Radicava.

Dr. Ichida, a renowned expert in the field of ALS and Alzheimer’s disease, praised the results of the study, stating, “PrimeC increased the survival rate to the level of the healthy control, and that got us very excited.” His work, which utilizes induced pluripotent stem cells (iPSCs), represents a cutting-edge approach to ALS research and drug development.

iPSC-derived Models Provide Hope for ALS Patients

NeuroSense’s PrimeC has demonstrated its potential to offer a much-needed therapy for ALS patients. This groundbreaking research, conducted in collaboration with a leading expert like Dr. Ichida, reinforces the compound’s standing as a leading ALS drug candidate. The results are a testament to the dedication and innovation driving the fight against neurodegenerative diseases.

The study’s use of iPSCs underscores the importance of cellular reprogramming in drug development. Induced pluripotent stem cells (iPSCs) can be generated from patient-specific cells, such as skin or blood cells, and differentiated into various cell types, including motor neurons. This allows for the creation of accurate in vitro models of diseases like ALS, providing a platform for drug screening and testing.

Furthermore, iPSCs enable high-throughput, personalized drug screening on patient-derived nerve cells. This breakthrough technology is revolutionizing drug development, offering more accurate and efficient models for disease research and drug discovery.

Awaiting Phase 2b Clinical Results

NeuroSense is now eagerly awaiting the clinical topline results from its Phase 2b study of PrimeC in ALS treatment, known as PARADIGM. These results are expected in the fourth quarter of 2023 and hold the promise of advancing PrimeC one step closer to becoming a viable treatment option for ALS patients.

The collaboration between NeuroSense Therapeutics and Dr. Justin Ichida’s team at USC’s Stem Cell Ichida Lab represents a significant leap forward in the quest to find an effective treatment for ALS. PrimeC’s exceptional performance in improving motor neuron survival offers a glimmer of hope to those living with ALS and their families. As research continues to evolve, we may be one step closer to a breakthrough that could change the lives of ALS patients for the better. NeuroSense’s commitment to developing combined therapies targeting multiple pathways associated with neurodegenerative diseases shows promise for the future of ALS treatment.

Source: NeuroSense

To learn more about the market for iPSCs, view the “Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report – Market Size, Trends, and Forecasts 2023.”